Search results
Results from the WOW.Com Content Network
The majority of people struck with MDR-TB live in "resource-poor settings" and are denied treatment because international organizations have refused to make technologies available to countries who cannot afford to pay for treatment, the reason being that second line drugs are too expensive therefore treatment methods for MDR-TB are not ...
[8] [9] [10] Treatment of MDR-TB requires second-line drugs (i.e., fluoroquinolones, aminoglycosides, and others), which in general are less effective, more toxic and much more expensive than first-line drugs. [8] Treatment schedules for MDR-TB involving fluoroquinolones and aminoglycosides can run for two years, compared to the six months of ...
If these drugs are misused or mismanaged, multidrug-resistant TB (MDR-TB) can develop. MDR-TB takes longer to treat with second-line drugs (i.e., amikacin, kanamycin, or capreomycin), which are more expensive and have more side-effects. XDR-TB can develop when these second-line drugs are also misused or mismanaged and become ineffective.
Extensively drug-resistant TB is also resistant to three or more of the six classes of second-line drugs. [155] Totally drug-resistant TB is resistant to all currently used drugs. [ 156 ] It was first observed in 2003 in Italy, [ 157 ] but not widely reported until 2012, [ 156 ] [ 158 ] and has also been found in Iran and India. [ 159 ]
As of 2011, drug susceptibility testing is done in less than 5% of TB cases globally [3] Without testing to determine drug resistance profiles, MDR- or XDR-TB patients may develop resistance to additional drugs and can continue to spread the disease to others. TDR-TB is relatively poorly documented, as many countries do not test patient samples ...
Its potency is less than that of the current five first-line drugs (isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin) for treating tuberculosis and its cost is higher, but it is still useful in the treatment of multidrug-resistant tuberculosis. [8] PAS is always used in combination with other anti-TB drugs. [citation needed]
For the treatment of tuberculosis, cycloserine is classified as a second-line drug. Its use is only considered if one or more first-line drugs cannot be used. Hence, cycloserine is restricted for use only against multiple drug-resistant and extensively drug-resistant strains of M. tuberculosis.
Capreomycin is an antibiotic which is given in combination with other antibiotics for the treatment of tuberculosis. [1] Specifically it is a second line treatment used for active drug resistant tuberculosis. [1] It is given by injection into a vein or muscle. [1]